| GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study Z Temesgen, M Assi, FNU Shweta, P Vergidis, SA Rizza, PR Bauer, ... Mayo Clinic Proceedings 95 (11), 2382-2394, 2020 | 107 | 2020 |
| Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19 CC Campioli, EC Cevallos, M Assi, R Patel, MJ Binnicker, JC O’Horo Journal of Clinical Virology 130, 104577, 2020 | 92 | 2020 |
| Outcomes of COVID-19 with the Mayo Clinic model of care and research JC O’Horo, JR Cerhan, EJ Cahn, PR Bauer, Z Temesgen, J Ebbert, ... Mayo Clinic Proceedings 96 (3), 601-618, 2021 | 33 | 2021 |
| First clinical use of lenzilumab to neutralize GM-CSF in patients with severe and critical COVID-19 pneumonia Z Temesgen, M Assi, P Vergidis, SA Rizza, PR Bauer, BW Pickering, ... Medrxiv, 2020.06. 08.20125369, 2020 | 30 | 2020 |
| Impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections: an update and perspective MA Assi, M Doll, R Pryor, K Cooper, G Bearman, MP Stevens Infection control & hospital epidemiology 43 (6), 813-815, 2022 | 25 | 2022 |
| Lawsonella clevelandensis: an emerging cause of vascular graft infection R Ramesh, M Assi, ZE Garrigos, MR Sohail BMJ Case Reports CP 14 (2), e237350, 2021 | 8 | 2021 |
| Infection prevention and antimicrobial stewardship program collaboration during the COVID-19 pandemic: a window of opportunity M Assi, S Abbas, P Nori, M Doll, E Godbout, G Bearman, MP Stevens Current Infectious Disease Reports 23 (10), 15, 2021 | 7 | 2021 |
| 1138. retrospective cohort analysis of amphotericin B nephrotoxicity in kidney transplant recipients M Assi, D Engracia, I Yakubu, G Gupta, N Kurbanova, ODL Cruz Open Forum Infectious Diseases 5 (suppl_1), S341-S342, 2018 | 4 | 2018 |
| Transient hepatitis B surface antigenemia following immunization with heplisav-B CC Campioli, ZE Garrigos, M Assi, JR Go, RR Razonable, E Beam, J Yao, ... Mayo Clinic Proceedings: Innovations, Quality & Outcomes 5 (3), 542-547, 2021 | 3 | 2021 |
| Initial SARS-CoV-2 PCR crossing point does not predict hospitalization and duration of PCR positivity AR Eberly, DW Challener, FNU Shweta, M Fida, AC Boerger, M Assi, ... Journal of Microbiology, Immunology and Infection 54 (1), 77-80, 2021 | 2 | 2021 |
| Are we overlooking the use of oral ribavirin for respiratory syncytial virus infection following hematopoietic stem cell transplantation? M Assi, B Cornfield, D Engracia, H Chung, W Clark, J McCarty, FP Silveira, ... Current Treatment Options in Infectious Diseases 11, 188-198, 2019 | 1 | 2019 |
| Lenzilumab. Anti-GM-CSF monoclonal antibody, Treatment of chronic myelomonocytic leukemia, Treatment of COVID-19 ZT Abdul M. Kalaiger, Mariam Assi Drugs of the Future 47 (12), 887-892, 2022 | | 2022 |
| Lenzilumab. Anti-GM-CSF monoclonal antibody, Treatment of chronic myelomonocytic leukemia, Treatment of COVID-19 AM Kalaiger, M Assi, Z Temesgen Drugs of the Future 47 (12), 2022 | | 2022 |
| Investigational immunomodulatory therapies for COVID-19 M Assi, KM Koshy, W El Atrouni, K Burke, M Berg, A Opardija, ... Drugs of the Future 46 (9), 2021 | | 2021 |
| Investigational antiviral drugs for the treatment of COVID-19 ZT C.T.R. Vegivinti, M. Assi, R. Talwani, V. Koblizek, K. Burke Drugs of the Future 46 (9), 697-710, 2021 | | 2021 |
| 1838. Bare Below the Elbows vs. Sleeved Attire: A Pilot Study Comparing Microbial Flora of Healthcare Workers. M Assi, Y Major, O Hess, E Styslinger, T Srivastava, C Doern, K Cooper, ... Open Forum Infectious Diseases 6, 2019 | | 2019 |
| 2097. Do Catheter-Associated Bloodstream Infections Affect Patients’ Perception of Care? M Assi, N Kurbanova, R Qayyum Open Forum Infectious Diseases 5 (Suppl 1), S615, 2018 | | 2018 |
